▲ +253.23% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Acorda Therapeutics in the last 3 months. The average price target is $23.67, with a high forecast of $35.00 and a low forecast of $6.00. The average price target represents a 253.23% upside from the last price of $6.70.
The current consensus among 3 polled investment analysts is to hold stock in Acorda Therapeutics. This Hold consensus rating has held steady for over two years.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.